Aptose Biosciences Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Note 5 - Right-of-use Assets

Note 5 - Right-of-use Assets

9 Months Ended

Sep. 30, 2022

Notes to Financial Statements

Right-of-use Assets Disclosure [Text Block]

5.	Right-of-use assets:

		Nine months ended September 30, 2022				Year ended December 31, 2021

Right-of-use assets, beginning of period		$	1,860			$	1,848
Additions to right-of-use assets			91				12
Right-of-use assets, end of period			1,951				1,860
Accumulated amortization			(1,731	)			(1,395	)
Right-of use assets, NBV		$	220			$	465